Emmanuel Normant PharmD, PhD

Emmanuel Normant is currently the vice president of preclinical sciences at TG Therapeutics, a biotech focused on heme malignancies and located in New York. There, he oversees the early pipeline that includes a novel BTK inhibitor, an anti-PD-1 antibody and a bispecific antibody directed against CD19 and CD47. All three drugs are currently tested in phase 1 dose-escalation clinical trials in hematologic cancers.

Dr. Normant joined TG Therapeutics, bringing in 20 years of expertise in cancer biology, pharmacology, immuno-oncology, cancer epigenetics, and preclinical sciences. Emmanuel Normant received his pharmacy and Ph.D. degrees from Paris-Sorbonne University.